Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/ Refractory Acute Myeloid Leukemia (R/R AML)


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Perl, AE; Altman, JK; Cortes, JE; Smith, CC; Litzow, M; Baer, MR; Claxton, DF; Erba, HP; Gill, SC; Goldberg, SL; Jurcic, JG; Larson, RA; Liu, C; Ritchie, EK; Schiller, GJ; Spira, AI; Strickland, SA; Tibes, R; Ustun, C; Wang, ES; Stuart, RK; Rollig, C; Neubauer, A; Martinelli, G; Bahceci, E; Levis, MJ

Published Date

  • December 2, 2016

Published In

Volume / Issue

  • 128 / 22

Published By


  • 7

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Conference Location

  • San Diego, CA

Conference Start Date

  • December 3, 2016

Conference End Date

  • December 6, 2016